Introduction
============

Angiogenesis is essential for the development and progression of solid malignancies because it supports the nutrition and oxygenation of malignant cells ([@B01],[@B02]). It is an active, multistep process that includes the activation, proliferation, and migration of endothelial cells (ECs), and the activation of cytokines ([@B03]). Vascular endothelial growth factor (VEGF) is particularly important in this process through its interactions with tyrosine kinase receptors (TKRs), VEGF receptor (VEGFR)-1, and VEGFR2. The latter is an important regulator of EC recruitment, proliferation and survival ([@B01],[@B02],[@B04]). The level of circulating endothelial cells (CECs) in peripheral blood has been proposed as a noninvasive marker of angiogenesis ([@B05]).

An increase in the number of CECs has been reported in multiple myeloma ([@B06]) and myelodysplasia ([@B04]), but the prognostic value and meaning of this remain unknown. Rigolin et al. ([@B07]) found that CECs and endothelial precursor cells (EPCs) were increased in chronic lymphocytic leukemia compared to healthy controls, and that high levels of CECs were correlated with more aggressive disease and shorter time to first treatment. In addition, Ibrahim et al. ([@B08]) reported higher levels of CECs in the peripheral blood of acute myeloid leukemia patients than in healthy subjects. CEC levels were related to response to therapy and disease progression ([@B08]).

Chronic myeloid leukemia (CML) is a malignant clonal disorder of hematopoietic stem cells ([@B09]) that has been associated with high microvessel density and high serum VEGF levels. Indeed, the positive bcr-abl leukemic cells characteristic of CML may stimulate the migration of ECs from the bone marrow to the peripheral blood, mainly in blast crisis (BC). CEC levels in different phases of CML have not been extensively studied ([@B10]-[@B13]).

The aim of this study was to quantify CEC levels and *VEGF* gene expression in different phases of CML compared to healthy subjects. Our hypothesis was that CEC levels and *VEGF* gene expression were related to CML progression.

Subjects and Methods
====================

Patients
--------

Following approval by the Ethics Board of the Hospital das Clínicas, Faculdade de Medicina, Universidade de Sao Paulo, 84 patients with CML were enrolled in the study after providing written informed consent. Thirty-one (36.9%), with a median age of 46 years, were in the chronic phase (CP); 23 (27.4%) with a median age of 52 years were in blast crisis (BC); and 30 (35.7%) with a median age of 58 years were in the active phase (AP). *VEGF* gene expression was analyzed in 65 individuals, 25 (26%) in CP (median age 51 years); 14 (14%) in BC (median age 53 years); and 26 (27.0%) in AP (median age 58 years). All patients were classified according to the World Health Organization classification of myeloproliferative disorders after evaluation of peripheral blood, bone marrow aspirate, bone marrow biopsy, karyotyping and molecular analysis.

A control group of 50 volunteer apheresis platelet donors, 25 men and 25 women with a median age of 44 years (range 19 to 79 years) was evaluated for CEC. *VEGF* gene expression was determined in 32 volunteer platelet donors (17 men and 15 women with a median age of 49 years; range 21 to 77 years). No female controls were evaluated during a menstrual period. Patients diagnosed with BC were tested by flow cytometric immunophenotyping to determine whether the crisis was acute lymphoid or myeloid in lineage. Analysis of CECs and *VEGF* gene expression was carried out in different numbers of samples because performing the required molecular techniques was not feasible in some samples.

Blood samples
-------------

Venous blood samples (10 mL) from CML patients and control subjects were collected in pyrogen-free tubes containing ethylenediaminetetraacetic acid (EDTA).

Characterization of CECs
------------------------

### Procedure for flow cytometry

Eighty-four CML patients and 50 healthy volunteers were tested. The different subpopulations of CECs were assayed by four-color multiparametric flow cytometry using a specific monoclonal antibody (MoAb) panel and a lyze/wash technique previously described by Mancuso et al. ([@B14]).

In brief, 1×10^6^ cells were added to each of three different tubes. One contained 10 µL of a phycoerythrin-cyanine 5.1-conjugated anti-CD45 clone J33 antibody (CD45/PC5, 1:10; Immunotech, France). The second tube contained 10 µL fluorescein isothiocyanate (FITC)-conjugated anti-CD146 clone OJ79C antibody (CD146/FITC; Serotec, UK), 10 µL of phycoerythrin-conjugated anti-CD34 class III clone BIRMA-K3 antibody (CD34/PE; DakoCytomation, USA), 10 µL CD45/PC5 (1:10), and 10 µL allophycocyanin-conjugated anti-CD133 clone 293C3 antibody (CD133/APC; Milteny Biotec, USA). The third tube contained 10 µL of CD146/FITC, 20 µL of PE-conjugated anti-CD62e clone TEA2/1 antibody (CD62e/PE; BD Bioscience, USA), 10 µL CD45/PC5 (1:10), and 10 µL CD133/APC. All tubes were incubated in the dark for 20 min followed by red cell lysis by the addition of 2000 µL of BD lyzing solution diluted 1:10 in deionized water. The tubes were then centrifuged at 1000 *g* for 3 min and washed twice with 2000 µL of phosphate-buffered saline (PBS) containing 0.1% azide. Cells were resuspended in 400 µL 1% formaldehyde and 100,000 events per tube were read on a FACSCalibur flow cytometer (BD Biosciences, USA) and analyzed using CellQuest Pro software (BD Biosciences). Flow cytometer performance was monitored daily using CaliBRITE microbeads and reagent with the FACSComp software (BD Biosciences). All procedures were performed in duplicate to verify the reproducibility of the results.

### Validation of MoAb

All MoAb tests were validated with human umbilical vein endothelial cells (HUV-EC-C, ATCC CRL-1730; Manassas, USA) cultivated at our laboratory in 199/EBS medium complemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 µg/mL streptomycin.

### Analysis of endothelial cells

We first selected all living cells in a side-scatter (SSC)/CD45 plot to exclude platelets, dead cells, and debris. Then, we gated around a region corresponding to CD45^-^ negative and low SSC in order to exclude hematopoietic cells ([Figure 1](#f01){ref-type="fig"}) ([@B14]-[@B16]). Subsequently, we looked for CD146, CD34, CD62e, and CD133 expression in other 2D fluorescence plots from R2. EPCs were considered as CD45^-/dim^/CD146^+^/CD133^+^/CD34^+^/CD62e^-/+^ and mature (m)CECs as CD45^-/dim^/CD146^+^/CD62e^+/-^/CD133^-^/CD34^-^ ([Figure 2](#f02){ref-type="fig"}). The presence of the CD62e antigen characterized activated EPCs and mCECs. CECs were reported as a percentage of the total events after the exclusion of debris. To prevent bias, only percentage values were used in statistical analyses because the leukocyte count was highly variable in each group. The medians were 6.2×10^9^/L in the control group, 21.2×10^9^/L in the CP-CML group, 87.5×10^9^/L in the BC-CML group, and 6.1×10^9^/L in the AP-CML group.

![*Left*, Forward side scatter (FSC) *vs* side scatter (SSC) cytogram in dot plots showing region 1 (R1) gating mononuclear cells and excluding debris and (*right*) CD45^-/dim^ *vs* SSC. R2: region 2; PC5: phycoerythrin-cyanin 5.1.](1414-431X-bjmbr-48-06-00509-gf01){#f01}

![Flow cytometry analyses of endothelial cells in venous blood samples from chronic myeloid leukemia (CML) patients in blast crisis. *A1*, *A2* and *A3*, corresponding isotypic control. *B1*, endothelial precursor cells (EPCs) expressing CD45^-/dim^/CD146^+^/CD133^+^; and *B2*, CD45^-/dim^/CD146^+^/CD34^+^. *B3*, Characterization of activated mature circulating endothelial cells expressing CD45^-/dim^/CD146^+^/CD62e^+^ and mCEC (CD45^-/dim^/CD146^+^/CD62e^-^).](1414-431X-bjmbr-48-06-00509-gf02){#f02}

Detection of VEGF by real-time quantitative PCR
-----------------------------------------------

### Mononuclear isolates

Mononuclear cells were isolated from the buffy coats of venous blood samples obtained from 65 CML patients and 32 healthy donors. The steps included dilution of whole blood with an equal volume of PBS. Four parts of diluted blood was added carefully to three parts Ficoll-Paque Plus (GE Healthcare Life Science, UK) and centrifuged at 400 *g* for 30 min. The buffy coat cells were isolated by washing twice in PBS with centrifugation for 10 min at 100 *g*. Then, monocytes were counted in a Neubauer chamber, and 1×10^7^ cells were frozen at -20°C in 1.0 mL of Trizol reagent (Invitrogen, USA).

### RNA isolation

Cells were thawed at room temperature, with the subsequent addition of 200 µL of chloroform followed immediately by homogenization, and then resting for 3 min at room temperature. The homogenate was centrifuged at 11,800 *g* for 15 min at 4°C. The supernatant was transferred to a new 1.5 mL previously identified tube and 500 µL of isopropanol was gently added. Following incubation for 10 min at room temperature to promote precipitation of RNA, the mixture was centrifuged at 11,800 *g* for 10 min at 4°C. The supernatant was discarded and the RNA was washed in 1 mL of 75% ethanol diluted in diethylpyrocarbonate (DEPC)-treated water. After centrifugation for 5 min at 4°C for 7400 *g*, the supernatant was discarded, and the pelleted RNA was dried and resuspended in 50 µL DEPC-treated distilled water. To detect RNA degradation, an aliquot of each total RNA sample was run on an 0.8% agarose gel stained with ethidium bromide (EtBr). RNA was quantified at 260/280 nm using a spectrophotometer (ND-1000; Nanodrop, USA). Treatment of RNA samples with DNAse was performed according to the kit manufacturer\'s instructions (M610A; Promega Corporation, USA).

### Real-time quantitative PCR

Real-time quantitative PCR gene expression assay for VEGF was carried out using Taqman methodology (Hs00173626, Applied Biosystems, USA). We chose beta-glucuronidase (*GUSB*) as the control gene (4333767-F, Applied Biosystems). Amplifications were carried out in a volume of 12.5 µL using 3 µL of RNA (50 ng of RNA) and a SuperScript III Platinum One-Step Quantitative RT-PCR System kit (Invitrogen). The reactions were carried out in a Rotor-Gene RG 3000 thermal cycler (Corbett Research, Applied Biosystems) under standard conditions. Relative quantification was carried out using the comparative ΔΔCT method following the procedure described by Livak and Schmittgen ([@B17]). All samples were analyzed in duplicate, and the median was used for further calculations. KG1, a myeloid cell line, was used as positive control, and calibrators were added to each plate.

Statistical analysis
--------------------

Because of the non-normal distribution of the expression data (Shapiro-Wilk test), we used the nonparametric Kruskal-Wallis test and BioEstat 4.0 software (Sociedade Civil Mamirauá, Brazil) to compare medians and percentages of CEC subtypes and *VEGF* gene expression of the different phases of CML and healthy subjects. The significance level (α) was 5%, and Wilcoxon\'s test was used to compare the results of duplicate assays.

Results
=======

CECs
----

Fifty healthy subjects were analyzed, 25 (50%) males and 25 (50%) females with a median age of 46 years (range 19-79 years). The median percentages of CECs, EPCs, mCECs, and activated (a)CECs were 0.0059%, 0.0023%, 0.0022%, and 0.0021%, respectively. The BC group consisted of 23 patients, 13 (59%) males and 10 (41%) females, with a median age of 52 years (range 20-74 years). The median percentages of CECs, EPCs, mCECs, and aCECs were 0.0146%, 0.0035%, 0.0072%, and 0.0022%, respectively. There were 31 CP cases, 18 (56%) males and 13 (42%) females, with a median age of 52 years (range 19-82 years). The median percentages of CECs, EPCs, mCECs, and aCECs were 0.0098%, 0.0044%, 0.0033%, and 0.0010%, respectively. In the AP group, there were 30 patients, 16 (53.3%) males and 14 (46.7%) females, with a median age of 58 years (range 27-81 years). The median percentages of CECs, EPCs, mCECs, and aCECs were 0.0059%, 0.0023%, 0.0023%, and 0.0011%, respectively. The BC group had significantly higher percentages of CECs and mCECs than the control (P\<0.01) and AP (P\<0.01) groups. There were no significant differences in the percentages of CECs in the CP and AP groups and the healthy subjects. No significant differences were found in the results of duplicate CEC data acquired by flow cytometry (not shown). Minimum and maximum percentages of CECs are shown in [Table 1](#t01){ref-type="table"}.

VEGF
----

### Efficiency of real-time PCR

The efficiency of real-time PCR was tested in serial dilutions of RNA from the KG1 cell line, demonstrating 98% efficiency for the *VEGF* gene with an R^2^ of 0.99 and 100% efficiency for the endogenous *GUSB* gene with an R^2^ of 0.99.

### VEGF expression

Thirty-two healthy subjects were analyzed, 17 (53.1%) males and 15 (46.9%) females with a median age of 51 years (range 21-77 years). The median value of VEGF expression was 0.145 (range 0.030-0.760). The BC group consisted of 14 patients, 11 (78.6%) males and 3 (21.4%) females with a median age of 53 years (range 24-67 years). The median *VEGF* expression was 0.245 (range 0.010-2.110). There were 25 cases in the CP group, 14 (56%) males and 11 (44%) females with a median age of 52 years (range 19-82 years). The median *VEGF* expression was 0.330. There were 26 patients in the AP group, 12 (46.1%) males and 14 (53.9%) females with a median age of 58 years (range 26-81 years). The median *VEGF* expression was 0.320. *VEGF* gene expression was significantly higher in all phases of CML than it was in the healthy patients. There were no statistically significant differences in *VEGF* expression in the different phases of CML. Minimum and maximum percentages of *VEGF* gene expression are shown in [Table 1](#t01){ref-type="table"}.

Discussion
==========

The initial study hypothesis was that a significant increase in CECs in peripheral blood occurred at the expense of EPCs in BC of CML. This increase was thought to be related to the increased vascular diameter observed at that stage and a result of neovascularization and increased microvascular density in the bone marrow microenvironment, which are directly related to mobilization of EPCs ([@B10],[@B13]). However, this hypothesis was not confirmed. The increase of CECs in peripheral blood during BC was at the expense of mCECs, leading us to believe that this CEC subtype may have been derived from the mobilization of newly formed vessels or by recruiting neighboring vessels to neoangiogenesis, with the release of mCECs. This activity has previously been demonstrated in murine tumor models ([@B18]).

To corroborate the CEC findings, we analyzed *VEGF* gene expression. This growth factor is an important mediator of angiogenesis and is involved in the pathogenesis of myeloid malignancies, including CML ([@B19]). However, there was an increase of *VEGF* in all phases of CML. Our results are consistent with previous studies demonstrating that the malignant cells of CML overexpress *VEGF*. Thus, this marker has not proven useful to discriminate the different stages of CML. However, we observed a significant increase in *VEGF* in myeloid BC compared to lymphoid BC, corroborating the results reported by Krauth et al. ([@B19]). Those authors suggest that the lymphoid BC has a better prognosis than myeloid BC in CML. Wierzbowska et al. ([@B05]) suggested that endothelial cells may enhance the survival and proliferation of leukemic blasts and mediate chemotherapy resistance in acute myeloid leukemia (AML). Those authors found a large numbers of CECs in the peripheral blood of AML patients, and their levels were correlated with disease status and response to therapy. Recently, Ibrahim et al. ([@B08]) demonstrated that aCEC and EPC levels were higher in AML patients than in healthy controls (P\<0.0001 and P\<0.001, respectively). They also reported that CEC levels were correlated with disease status in AML.

In line with our results, Rigolin et al. ([@B07]) demonstrated increased numbers of EPCs in chronic lymphocytic leukemia (CLL) compared to healthy controls. Higher CEC levels were associated with more aggressive disease and shorter time to first treatment (P\<0.001).

Our study found that quantification of CECs in peripheral blood was useful for predicting and identifying early progression of CML to BC, in contrast to VEGF, a variable that was high at all stages.

Despite the significant results observed in our study, we believe it is important to conduct a prospective study with patient follow-up from diagnosis through treatment to determine the percentages and monitor CEC types and *VEGF* gene expression. Thus, one could trace variations in those results and the impact of those variables at each stage in the progression of CML. In addition, such a study could assess, and increase our understanding of, the behavior of those variables in patients refractory to treatment and help to improve their management.
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